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 University of Minnesota Libraries Response to request for comment on 
EPA-HQ-OA-2018-0259-0025 ​“Strengthening Transparency in Regulatory Science” 
 
Date: August 28, 2018 
 
Dear Acting Administrator Wheeler: 
 
The University of Minnesota Libraries writes in response to the proposed rule change 
EPA-HQ-OA-2018-0259-0025 (“Strengthening Transparency in Regulatory Science”), published 
in the Federal Register on April 30, 2018.  
The proposed rule proposes to support increased transparency, further reproducibility, and 
promote open science. Although the rule states that it “takes into consideration the policies or 
recommendations of third party organizations who advocated for open science,” it does not take 
into consideration the intent behind calls for openness in scientific research. 
We strongly support open science, but recognize that not all research data can and should be 
made available. The open science community supports the general principle that data should be 
"as open as possible, as closed as necessary” (European Commission Directorate-General for 
Research and Innovation. (2016). H2020 Programme: Guidelines on FAIR Data Management in 
Horizon 2020. Retrieved August 13, 2018 from 
http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/oa_pilot/h2020-hi-oa-
data-mgt_en.pdf). 
We are concerned that if the EPA only considers data that is open to the public in their 
decision-making process for regulations/policies, studies that were conducted with human 
subjects (due to the informed consent process) would be eliminated from consideration. 
Epidemiological data are ​the gold standard that drives and is critical to regulatory decisions, but 
cannot be made public or shared due to informed consent.  
The proposal also allows the EPA to be less conservative with dose response models, opening 
up the possibility for additional harms to human health and the environment. 
Supporters of open science recognize the need for some data to be “closed”, particularly those 
which involve human subjects or personally identifiable information.  That data are not made 
publicly available does not indicate that the data are not scientifically sound. Supporters of open 
science do not reject peer-reviewed studies simply because the underlying data cannot be 
made publicly available. As written, the proposed rule would prevent the EPA from using the 
best available science when drafting regulations. We urge the Acting Administrator to withdraw 
the rule. 
In what follows, we respond to EPA’s solicitation for comment on various aspects of the 
proposed rule.  
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 EPA solicits public comment on: 
I. Which criteria the Agency should use to base any exceptions, including whether 
case-by-case exceptions may be appropriate. 
A. While we support transparency generally, the broad implementation of a rule 
enforcing sharing with only case-by-case exceptions is problematic. In order to 
share data, individual data sets must be considered independently as well as in 
context of other available data.  
1. These caveats are noted within the documents listed in footnote 8. The 
documents the rule cites do not propose public access to all data, but 
public access when it is reasonable to do so. This is explicitly stated in 
EPA’s Plan to Increase Access to Results of EPA-Funded Scientific 
Research, “While the Agency strives to increase access to its research 
results, it recognizes, consistent with the OSTP Memo, that Federal 
agencies have a responsibility to protect confidentiality and personal 
privacy, respect proprietary interests and property rights, and balance 
between the value of providing long-term access and its associated costs. 
It is important to recognize that some research data cannot be made fully 
available to the public but instead may need to be made available in more 
limited ways, e.g., establishing data use agreements with researchers that 
respect necessary protections. ​Whether research data are fully 
available to the public or available to researchers through other 
means does not affect the validity of the scientific conclusions from 
peer-reviewed research publications.​ [emphasis added]” 
(Environmental Protection Agency. (November 29, 2016). Plan to 
Increase Access to Results of EPA-Funded Scientific Research. 
Retrieved from 
https://www.epa.gov/sites/production/files/2016-12/documents/epascientifi
cresearchtransperancyplan.pdf​, p. 4) 
B. As described later in this response, there would need to be exceptions for any 
data involving personally identifiable information, including both primary and 
secondary identifiers, or data where consent for broader sharing was not sought 
among initial participants at the time of enrollment. This would include the 
majority of data used by EPA to establish existing regulations. 
C. The proposed rule gives the authority to make case-by-case exemptions for 
“significant regulatory decisions” to the EPA Administrator. Granting this level of 
authority to a single person does not allow for appropriate oversight. We would 
request that in the event that exemptions need to be reviewed that they are 
delegated to a committee of expert scientists who perform similar work. 
II. Whether and to what extent these requirements, or other provisions and policies, should 
apply to other stages of the rulemaking process, including proposed rules, as well as to 
other types of agency actions and promulgations, such as guidance. 
A. For all of the reasons outlined in this response, we do not believe the rule should 
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 be applied.  
B. The use of valid scientific research data should be fundamental in the 
decision-making process. However, the analysis and interpretation of research 
data are a complicated and nuanced undertaking which requires in-depth 
expertise and a range of perspectives. Data should only be used in rulemaking 
where it has been subject to rigorous evaluation and interpretation by a range of 
impartial, qualified experts. This process is already undertaken during the 
scholarly peer review process.  
C. Encouraging openness with data going forward is appropriate. However, it will 
never be reasonable to expect that all data would be made publicly available, 
since it could necessarily include private health information about individuals that 
is protected by the Health Insurance Portability and Accountability Act (45 C.F.R. 
§ 164 (2016). 
D. We concur with the Association of American Medical Colleges (AAMC), 
Association of American Universities (AAU), Association of Public and Land-grant 
Universities (APLU), and Council on Governmental Relations (COGR) in their 
July 11, 2018 statement “Re: Docket Number EPA-HQ-OA-2018-0259-0025, 
Strengthening Transparency in Regulatory Science,” which states that “[e]ven the 
strongest and most sincere supporters  of the open science movement have 1
recognized that there is value in research for which underlying data are not made 
publicly available and acknowledge an imperative to leverage all science to 
develop policies and regulations.” 
(https://www.aamc.org/download/490086/data/aamceparesponsetonprm7-11-18.
pdf) 
III. Whether a narrower scope of coverage would be appropriate, such as only final 
regulations that are determined to be “major” under the Congressional Review Act, or 
“economically significant” under EO 12866. 
A. The proposed rule cites Exec. Order No. 13563, 76 FR 3821 (Jan. 21, 2011). 
‘‘Our regulatory system must protect public health, welfare, safety, and our 
environment while promoting economic growth, innovation, competitiveness, and 
job creation. It must be based on the best available science.’’ However, “best 
available” may not be compatible with a requirement for public access. Applying 
a rule that prohibits the use of “best available” data simply because the data 
cannot be made publicly available is inappropriate for any regulation, particularly 
those that are considered “major” and will be expected to have “major” effects on 
the environment. 
B. In order to rely on the best evidence to develop guidelines and regulations, EPA 
could conduct systematic reviews to critically evaluate all available published and 
unpublished research. This is established practice in federal agencies, notably 
the Agency for Healthcare Research and Quality (AHRQ) with the Department of 
Health and Human Service and their Evidence-based Practice Centers (EPC) 
1 Ioannidis, J.P.A. (2018). All science should inform policy and regulation. ​PLOS Medicine. 15​(5): 
e1002576. https://doi.org/10.1371/journal.pmed.1002576.  
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 Evidence Based Reports. Such reviews may not involve querying the initial raw 
data, but instead incorporate critical appraisal of research methods to assess for 
bias and determine the validity of evidence. To further enhance the EPA’s 
commitment to transparency, the full research methods of any review undertaken 
to develop guidelines or rules should be registered in advance as a protocol and 
be open to public comment.  
1. We note that the EPA currently conducts systematic reviews, and provide 
a short list of examples to demonstrate that EPA researchers are familiar 
with systematic review and recognize its validity and importance:  
a) U.S. EPA Office of Chemical Safety and Pollution Prevention. 
Application of Systematic Review in TSCA Risk Evaluations. 
(2018). EPA Document# 740-P1-8001. Available at: 
https://www.epa.gov/sites/production/files/2018-06/documents/fina
l_application_of_sr_in_tsca_05-31-18.pdf 
b) U.S. EPA. Thayer, Kris. (2017). Systematic Review for Chemical 
Assessments: Core Elements and Considerations for Rapid 
Response. Available at: 
https://www.epa.gov/sites/production/files/2018-04/documents/epa
_comptox_cop_v1_nov_16_2017_v4.pdf 
c) U.S. EPA. Systematic Review of Chloroprene. U.S. Environmental 




d) U.S. EPA. Systematic Review Protocol for the IRIS Chloroform 
Assessment (Inhalation) (Preliminary Assessment Materials). U.S. 
Environmental Protection Agency, Washington, DC, 
EPA/635/R-17/486, 2018. Available at: 
h​ttps://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=3386
53  
IV. Whether certain categories of regulation should be excluded from coverage, such as 
those that merely reaffirm an existing standard, or some other category. 
A. There is potential for this rule to be used to erase essentially all existing 
regulations, due to issues in making the data used in their creation publicly 
available. Because it is unethical to expose participants to likely harms, such as 
environmental contaminants previously found to cause illness, these data could 
not be recreated and additional studies on the topic could not be conducted (e.g., 
it would be unethical to do a randomized control trial to study the effects of 
consuming lead chips on children). 
B. For studies involving human subjects, participants agree to the study based on 
specific terms for how they will be treated and how their data will be used 
(informed consent). In order to make data from these studies openly available, all 
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 participants would need to be informed and agree to allow their data to be used 
in this way. This would be a challenge for many of the longitudinal studies that 
EPA regulations are based on.  
C. Additionally, the informed consent agreements that participants sign indicate the 
period of time in which their data will be stored.  If this period has passed, the 
researchers were obligated to destroy this data. We reiterate that not having the 
raw data available does not in any way negate the validity of a study that has 
undergone peer review. 
V. Whether the provisions of the proposed rule should apply to individual part adjudications, 
enforcement activities, or permit proceedings when EPA determines that these 
provisions are practical and appropriate and that the actions are scientifically or 
technically novel or more likely to have precedent-setting influence on future actions 
A. We ask EPA to define what they would consider “practical.” If they have 
precedent-setting influence, we suggest that studies could highlight their 
methods, but there cannot be a carte blanche expectation that raw data will be 
released.  
VI. The definitions of "pivotal regulatory science," and "dose response data and models" and 
how to implement such definitions. 
A. We are concerned that the rule does not recognize existing definitions for these 
terms. Until EPA has internally agreed to definitions for these terms, 
requirements for what data can be used should not be instituted.  
B. “Dose response data and models” are well-defined concepts. The dose-response 
relationship, “the relationship between the degree of response of the biological 
system and the amount of toxicant administered,” is in fact considered to be “the 
most fundamental and pervasive concept in toxicology” (Casarett, L. J., Doull, J., 
& Klaassen, C. D. (2008). Casarett and Doull's toxicology: The basic science of 
poisons. New York: McGraw-Hill.). The controversial aspect of these data and 
models are the underlying assumptions made, particularly in terms of low-dose 
toxicity.  
1. Historically, the EPA rightly has been conservative in its assumptions, 
meaning that it errs on the side of protecting human health by assuming 
that where there is insufficient evidence to rule out harm, one must 
assume harm. This is particularly true when considering regulations that 
will have an effect on human health and safety. We believe that the 
approach EPA has historically taken is appropriate and should be 
maintained.  
2. The Rule notes the “growing empirical evidence of non-linearity in the 
concentration-response function for specific pollutants and health effects,” 
but does not provide any reference to that evidence.  
3. The reference to “considering the breadth of dose response data and 
models used” would seem to reflect a change to the EPA’s traditional 
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 practice of opting for a protective stance.  
4. Dose-response relationships are used to predict the likelihood and 
magnitude of negative health consequences for individuals or broader 
populations. Conservatism assumes that individuals may be exposed to 
risk at lower doses. Conservative assumptions are pivotal, since, as the 
EPA notes in its Exposure Factors Handbook (U.S. EPA. Exposure 
Factors Handbook 2011 Edition (Final Report). U.S. Environmental 
Protection Agency, Washington, DC, EPA/600/R-09/052F, 2011.), 
conservative assumptions "provide the basis for measures protective of 
human health."  
VII. How to incorporate stronger data and model access requirements into the terms and 
conditions of cooperative agreements and grants. 
A. In response to a memorandum from the White House Office of Science and 
Technology Policy in 2013 (“Expanding Public Access to the Results of Federally 
Funded Research”), EPA, along with more than 20 other federal departments 
and agencies, developed a Plan to Increase Access to Results of EPA-Funded 
Scientific Research 
(​https://www.epa.gov/sites/production/files/2016-12/documents/epascientificrese
archtransperancyplan.pdf​).  Two sections that address current sharing of 
information are copied below: 
1. “EPA has a long history of collaboration in scientific research and is a 
leader in providing access to environmental information to encourage 
better decisions and a more informed public. Transparency is a core EPA 
value. The Agency already makes publicly available much of the Agency’s 
scientific and technical work, including information that supports 
regulatory decisions. For example, EPA provides all materials and 
scientific information supporting each regulation in public dockets, which 
are publicly available for comment at ​www.regulations.gov​. In addition, 
the Agency maintains an enterprise dataset metadata catalog (the 
Environmental Dataset Gateway (EDG) at 
https://edg.epa.gov/metadata/catalog/main/home.page​) through which 
thousands of EPA datasets are publicly available. EPA’s Enterprise 
Information Management Policy (EIMP), adopted March 3, 2015, codifies 
the Agency’s approach to facilitating access to data held in EPA 
information systems. Appendix D describes, in more detail, a small 
sample of EPA’s extensive ongoing efforts to be transparent and to 
increase access to environmental information.” (page 4) 
2. “​While the Agency strives to increase access to its research results, 
it recognizes, consistent with the OSTP Memo, that Federal agencies 
have a responsibility to protect confidentiality and personal privacy, 
respect proprietary interests and property rights, and balance 
between the value of providing long-term access and its associated 
costs​. It is important to recognize that some research data cannot be 
made fully available to the public but instead may need to be made 
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 available in more limited ways, e.g., establishing data use agreements 
with researchers that respect necessary protections. Whether research 
data are fully available to the public or available to researchers through 
other means does not affect the validity of the scientific conclusions from 
peer-reviewed research publications.” [emphasis added] 
B. We strongly support the implementation of the OSTP memorandum and EPA’s 
Plan to Increase Access to Results of EPA-Funded Scientific Research 
(​https://www.epa.gov/sites/production/files/2016-12/documents/epascientificrese
archtransperancyplan.pdf​). The language emphasized above reflects EPA’s 
understanding of the need for maintaining balance between the desire to public 
access to data and the responsibility to protect data providers their subjects. The 
proposed rule extends the intent for public access beyond reasonable 
expectations.  
VIII. How it can build upon other federal agencies' policies regarding grantee and cooperator 
requirements for data access and data sharing. 
A. We are unsure what is meant by this statement. As of January 2017, the EPA, 
along with more than 20 other federal agencies and departments, created a plan 
for public access to the results of research they fund (Holdren, JP. (January 9, 
2017). Retrieved August 6, 2018 from 
https://obamawhitehouse.archives.gov/sites/default/files/microsites/public_access
-report_to_congress-jan2017-final.pdf​). Enforcement of this policy would increase 
the amount of data that can be made openly available.  
B. Neither EPA, nor the federal government as a whole, funds all relevant science 
for protection of human health and the environment. Data resulting from research 
funded through sources other than EPA may be “best available” science and per 
EPA’s current directives, should form the basis of new regulations. However, this 
research would not be subject to federal data access and sharing requirements 
and it is unreasonable to expect that anyone doing research that may one day be 
important for regulatory science would anticipate the importance for this future 
use. These researchers would not be subject to current public access plans and 
may be unable to prepare their data in a way that it could be made publicly 
available, whether because their agreements with human subjects do not permit 
this or because a lack of funding would prevent them from taking the steps 
necessary to enable the data to be made public. 
IX. Suggestions for a platform that would enable the Agency to implement the provisions of 
this proposal related to increasing public access to EPA-funded data. 
A. Aggregating sensitive health data onto one platform would unnecessarily 
increase risks to human subjects. Data breaches at the Office of Personnel 
Management (OPM) 
(https://www.opm.gov/cybersecurity/cybersecurity-incidents/) and other 
commercial organizations (e.g., Equifax, Yahoo) demonstrate that no platform 
can ever be completely secure.  
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 B. Numerous issues will need to be considered if a platform is developed for 
providing public access to EPA-funded data, especially if the goal is long-term 
preservation. Guidelines would need to be established as to how long the data 
would be held; it may be unreasonable to suggest these data will be available 
forever. Further, such a repository would need to provide mechanisms for file 
format migration and would need to ensure that data remain un-corrupted and 
readable. These are time-intensive and resource-heavy activities and may 
require dedicated staff to ensure they are completed. Ideally, dedicated data 
curators would curate the data upon deposit to check that adequate 
documentation has been provided such that the data can be understood and 
checksums completed to make sure no data is missing or there are errors.  
X. Methodologies and technologies designed to provide protected access to identifiable 
and sensitive data, such as individual health data, and on commenters[‘] experience with 
the use of such methodologies and technologies and their strengths and limitations. 
A. We cannot state strongly enough that there is no such thing as truly anonymized 
data. “De-identified” and “anonymous” data can be re-identified. This has been 
clearly shown by researchers at the University of Melbourne, who were able to 
re-identify individual patients based on de-identified data published by Australia’s 
federal Department of Health (Culhane, C., Rubinstein, B.I.P., & Teague, V. 
(2017). Health data in an open world. https://arxiv.org/abs/1712.05627).The Data 
Privacy Lab at Harvard University lists numerous projects in which they explore 
the possibility of identifying participants in “anonymized” systems or studies.  As 
an example, Dr. Latanya Sweeney was was able to re-identify 42% of 
supposedly anonymized participants in the Personal Genome Project (Sweeney, 
L., Abu, A., & Winn, J. (2013). Identifying Participants in the Personal Genome 
Project by Name (A Re-identification Experiment). 
https://arxiv.org/abs/1304.7605) 
B. We reiterate that government systems and public sector organizations with highly 
personal data have been breached and there is no reason to believe any system 
could be completely secure. 
XI. How to balance appropriate protection for copyrighted or confidential business 
information, including where protected by law, with requirements for increased 
transparency of pivotal regulatory science. 
A. Data with intellectual property or confidentiality concerns should not be shared. 
The sharing of data containing patentable information or trade secrets should not 
be required due to the potential negative economic implications of such a 
requirement.  
XII. Whether there are other compelling interests besides privacy, confidentiality, national 
and homeland security that may require special consideration when data is being 
released. 
A. The aforementioned intellectual property considerations must also be noted.  
B. As research is increasingly the product of international collaboration, differing 
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 regulations and requirements worldwide must also be considered.  
C. Where secondary data analysis is being conducted, data use agreements 
prohibit broader dissemination of data, which would also prohibit data from being 
released publicly.  
XIII. How the prospective or retrospective application of the provisions for dose response 
data and models or pivotal regulatory science could inadvertently introduce bias 
regarding the timeliness and quality of the scientific information available. 
A. Retrospective application and the process for this, is not described within the text 
of the rule. 
B. Retrospective application of the provision would directly introduce bias regarding 
the timeliness and quality of the scientific information available, as applying the 
rule would remove most data from consideration.  
C. No data sharing rule should ever be applied retroactively. Enforcement of data 
sharing for previously completed projects would introduce undue financial burden 
on principal investigators and may be largely impossible. IRB-approved studies 
include provisions regarding disposal of data following study completion. 
Researchers abiding by these provisions would have securely deleted and 
disposed of all raw data in the allotted time following project completion. The 
retroactive imposition of this rule would invalidate well-conducted research to the 
detriment of public health.  
XIV. How to address a circumstance in which EPA has a statutory requirement to make a 
determination for which scientific information publicly available in a manner sufficient for 
independent validation does not exist. 
A. Scientific papers are part of the scholarly record that have undergone peer 
review, typically double blind peer review, to ensure their quality. This 
well-established practice is the standard for ensuring unbiased, rigorous vetting 
of scholarly content prior to publication.  
XV. Any additional implementation challenges not discussed in this notice that commenters 
may be aware of as well as suggestions for addressing them. 
A. The inability to make data secure makes it unreasonable to expect that health 
data would be made public. No system is ever fully secure. 
XVI. Whether the disclosure requirements applicable to dose response data and models in 
the proposed rule should be expanded to cover other types of data and information, 
such as for example economic and environmental impact data and models that are 
designed to predict the costs, benefits, market impacts and/or environmental effects of 
specific regulatory interventions on complex economic or environmental systems. 
A. If the economic and environmental impact data and models described here would 
be developed by EPA scientists, they would seem to be subject to the federal 
Open Data Policy.  In general, economic and environmental impact data do not 
necessarily include data from individual humans and therefore do not pose the 
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 challenges we have outlined in our above response.  
B. However, again, there are issues with mandating sharing when i) the research 
was conducted without intent to inform a rule; ii) was conducted without a 
pre-existing mandate to share data; iii) was conducted a long time ago and 
accessing the data for the research is impossible. There will always be reasons 
why not all data can be shared and a strict mandate for public access will 
needlessly remove important research from consideration.  
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